2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-11063S
    Fingolimod-d4 1346747-38-3 99.16%
    Fingolimod-d4 is the deuterium labeled Fingolimod. Fingolimod (FTY720 free base) is a brain-penetrant sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant.
    Fingolimod-d4
  • HY-111303
    CHIC35 848193-72-6 98%
    CHIC35, an analog of EX-527, is a potent and selective inhibitor of SIRT1 (IC50=0.124 μM). CHIC35 shows potential selective inhibition against SIRT1 over SIRT2 (IC50=2.8 μM) or SIRT3 (IC50>100 μM). CHIC35 has anti-inflammatory effects and can be used for CHARGE syndrome research.
    CHIC35
  • HY-111516
    MGV354 98%
    MGV354 is a soluble guanylate cyclase (sGC) activator with EC50s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively.
    MGV354
  • HY-111749
    JAK-IN-4 1400877-37-3 98%
    JAK-IN-4 is a proagent of a JAK inhibitor, effective in murine collagen induced arthritis model.
    JAK-IN-4
  • HY-112243
    Cimpuciclib 2202767-78-8 98%
    Cimpuciclib is a selective CDK4 inhibitor (IC50: 0.49 nM) that has anti-tumor activity.
    Cimpuciclib
  • HY-112617
    Thalidomide-O-amido-PEG2-C2-NH2 1957235-74-3
    Thalidomide-O-amido-PEG2-C2-NH2 incorporates an E3 ligase ligand and a linker, can be an immunomodulater for the research of cancer.
    Thalidomide-O-amido-PEG2-C2-NH2
  • HY-112874
    BMS-681 847998-92-9 98%
    BMS-681 is an orthosteric antagonist of CC chemokine receptor 2 (CCR2). BMS-681 restricts the movement of the extracellular end of TM6 by stabilizing TM7. TM7 and TM6 are the main components of the orthosteric binding site. BMS-681 can be used to study inflammatory neurodegenerative diseases and cancer.
    BMS-681
  • HY-115876
    BTK-IN-5 2145152-06-1 98%
    BTK-IN-5 is a covalent BTK inhibitor for researching medical conditions such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes.
    BTK-IN-5
  • HY-119935
    JAK3 covalent inhibitor-1 2300106-50-5 98%
    JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs.
    JAK3 covalent inhibitor-1
  • HY-128353
    ROR agonist-1 2361528-74-5 98%
    ROR agonist-1 is a potent and orally bioavailable inverse agonist of the retinoic acid receptor-related orphan receptor C2 (RORC2), inhibition of IL-17A production from human primary TH 17 cells with a pIC50 of 7.5.
    ROR agonist-1
  • HY-128829
    Kv3 modulator 2 2101321-76-8 99.92%
    Kv3 modulator 2 (formula (I)) is a potent Kv3 channels modulator extracted from patent WO2018109484A1, compound formula (I) , has analgesic activity and is used in the prophylaxis or treatment of related disorders.
    Kv3 modulator 2
  • HY-128954
    Sulfo-PDBA-DM4 1461704-01-7
    Sulfo-PDBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody agent conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker.
    Sulfo-PDBA-DM4
  • HY-12995A
    (S)-BI 665915 1360550-05-5 98%
    (S)-BI 665915 is an orally active oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 1.7 nM for FLAP binding. (S)-BI 665915 inhibits FLAP functional in human whole blood with an IC50 of 45 nM. (S)-BI 665915 demonstrates an excellent cross-species agent metabolism and pharmacokinetics (DMPK) profile and a dose-dependent inhibition of LTB4 production.
    (S)-BI 665915
  • HY-130255
    BTK inhibitor 13 2376726-26-8 98%
    BTK inhibitor 13 (compound 8) is a potent and selective Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 1.2 nM.
    BTK inhibitor 13
  • HY-131247
    Bcl-2-IN-2 2383085-86-5 98%
    Bcl-2-IN-2 is a potent and selective Bcl-2 inhibitor with an IC50 of 0.034 nM and also inhibits Bcl-xL with an IC50 of 43 nM, showing >1000-fold selectivity for Bcl-2 over Bcl-xL.
    Bcl-2-IN-2
  • HY-131340
    LASSBio-1632 3029936-02-2 98%
    LASSBio-1632 is a new anti-asthmatic lead candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-α production in the lung tissue. LASSBio-1632 (7j) displays high experimental BBB permeability across BBB through passive diffusion.
    LASSBio-1632
  • HY-132195
    RORγt inverse agonist 14 2672496-70-5 98%
    RORγt inverse agonist 14 (8e) is a potent, orally active and selective RORγt inverse agonist (EC50 of 2.5 nM) with anti-inflammatory activity. RORγt inverse agonist 14 is used in the study for rheumatoid arthritis and psoriasis.
    RORγt inverse agonist 14
  • HY-132196
    BTK inhibitor 18 98%
    BTK inhibitor 18 is a potent, selective,orally active and covalent Btk inhibitor with a IC50 of 142 nM. BTK inhibitor 18 has anti-inflammatory activities.
    BTK inhibitor 18
  • HY-132230
    GSK040 2752331-09-0 98%
    GSK040 is a potent and highly selective BET BD2 inhibitor, with a pIC50 of 8.3. GSK040 shows more than 5000-fold selectivity for BET BD2 over BET BD1 (pIC50=4.6). GSK040 can be used for the research of oncology and immunology diseases.
    GSK040
  • HY-132882
    ARN19689 2320521-34-2 98%
    ARN19689 is a potent, selective, orally active and non-covalent inhibitor of N Acylethanolamine-Hydrolyzing Acid Amidase (NAAA), with an IC50 of 42 nM. ARN19689 is a promising pharmacological tool to be further investigated in the field of inflammatory conditions.
    ARN19689
Cat. No. Product Name / Synonyms Application Reactivity